GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2cureX AB (OSTO:2CUREX) » Definitions » Operating Margin %

2cureX AB (OSTO:2CUREX) Operating Margin % : -10,629.89% (As of Sep. 2023)


View and export this data going back to 2017. Start your Free Trial

What is 2cureX AB Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. 2cureX AB's Operating Income for the three months ended in Sep. 2023 was kr-9.25 Mil. 2cureX AB's Revenue for the three months ended in Sep. 2023 was kr0.09 Mil. Therefore, 2cureX AB's Operating Margin % for the quarter that ended in Sep. 2023 was -10,629.89%.

The historical rank and industry rank for 2cureX AB's Operating Margin % or its related term are showing as below:

OSTO:2CUREX' s Operating Margin % Range Over the Past 10 Years
Min: -35703.33   Med: -22078.26   Max: -8453.19
Current: -13441.37


OSTO:2CUREX's Operating Margin % is ranked worse than
92.6% of 1027 companies
in the Biotechnology industry
Industry Median: -166.59 vs OSTO:2CUREX: -13441.37

2cureX AB's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

2cureX AB's Operating Income for the three months ended in Sep. 2023 was kr-9.25 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 was kr-33.47 Mil.


2cureX AB Operating Margin % Historical Data

The historical data trend for 2cureX AB's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

2cureX AB Operating Margin % Chart

2cureX AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Operating Margin %
Get a 7-Day Free Trial - - - - -35,703.33

2cureX AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -94,325.00 -8,651.22 -64,976.92 -12,955.22 -10,629.89

Competitive Comparison of 2cureX AB's Operating Margin %

For the Biotechnology subindustry, 2cureX AB's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


2cureX AB's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 2cureX AB's Operating Margin % distribution charts can be found below:

* The bar in red indicates where 2cureX AB's Operating Margin % falls into.



2cureX AB Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

2cureX AB's Operating Margin % for the fiscal year that ended in Dec. 2022 is calculated as

Operating Margin %=Operating Income (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=-32.133 / 0.09
=-35,703.33 %

2cureX AB's Operating Margin % for the quarter that ended in Sep. 2023 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=-9.248 / 0.087
=-10,629.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


2cureX AB  (OSTO:2CUREX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


2cureX AB Operating Margin % Related Terms

Thank you for viewing the detailed overview of 2cureX AB's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


2cureX AB (OSTO:2CUREX) Business Description

Traded in Other Exchanges
Address
Fruebjergvej 3, Copenhagen, DNK, DK-2100
2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.

2cureX AB (OSTO:2CUREX) Headlines

No Headlines